Angle PLC

Parsortix enables CTC molecular characterisation

GUILDFORD, SURREY--(Marketwired - Nov 28, 2017) - Angle PLC (AIM: AGL) (OTCQX: ANPCY)

For immediate release

28 November 2017

AIM:AGL OTCQX:ANPCY

ANGLE plc ("the Company")

PARSORTIX™ SYSTEM ENABLES MOLECULAR DETECTION AND CHARACTERISATION OF CIRCULATING TUMOUR CELLS WHERE OTHER APPROACHES FAIL

Results demonstrate that harvested CTCs can be analysed without further purification steps

Study published in eighth peer reviewed paper detailing Parsortix™ use

ANGLE plc (AIM: AGL) (OTCQX: ANPCY), a world-leading liquid biopsy company, today announces that its Parsortix™ system is the subject of a further peer-reviewed publication in the journal Oncotarget, detailing work undertaken by Prof. Robert Zeillinger's Molecular Oncology Group at the Medical University of Vienna (Vienna). Prof. Zeillinger is a key opinion leader in the field of liquid biopsies use in oncology.

Prof Zeillinger's group developed and tested protocols to allow the molecular characterisation of the circulating tumour cells (CTCs) and residual blood cells harvested by the Parsortix™ system without the need to separate out the CTCs. This was only possible because the Parsortix™ system provides high purity cells with very efficient removal of white blood cells. With alternative approaches for CTC enrichment such as density gradient centrifugation, this has not been possible, as high levels of contaminating white blood cells remain with the CTCs captured.

Vienna had identified specific genes which were expressed preferentially on CTCs earlier and, evaluating a panel of such genes, were able to get positive results in 95% of primary (i.e. localised disease that has not spread) gynaecological cancer patient samples, 100% of recurrent gynaecological cancer patient samples and 92% metastatic breast cancer patient samples.

This workflow established by Prof. Zeillinger's group provides the opportunity not only for use in detection of cancer but also the molecular characterisation of CTCs for the purpose of assessing which drugs may be most effective for a patient during their disease progression.

The publication is available at https://angleplc.com/library/publications/

Professor Robert Zeillinger, Head of the Molecular Oncology Group at the Medical University of Vienna, commented: